Replies to post #2615 on Repros Therapeutics Inc (RPRX)

[Pre_Clinical]

The analyst Jonathan Aschoff posed as a doctor in order to obtain inside information on a clinical trial. He should be in jail. I wouldn't take any comparisons to him as a compliment.

[rstor1]

Well, considering that most of my market gains this year were from DNDN, I'm rather glad I didn't listen to him.

I am in a similar position but, in all fairness, that had more to do with timing than with anything else. For the MANY investors that bought in the teens and twenties, listening to the naysayers would have been the better move.

Regards,
Bob

[DewDiligence]

>I'm merely suggesting that something beyond intuition or smell should be your basis for slamming a stock. Back your opinion with legitimate arguments and I'll listen.<

Evidently, you think intuition is not an integral part of investing. I could not disagree more.